Engimmune Therapeutics

Engimmune Therapeutics is a private, preclinical-stage biotech focused on developing off-the-shelf soluble TCR engagers for oncology and autoimmune diseases. The company's core strength lies in its integrated AI-guided protein engineering and laboratory platforms, designed to overcome historical challenges in soluble TCR development like affinity, stability, and safety. Backed by leading life science investors Novo Holdings and Pureos Bioventures, Engimmune is advancing a preclinical lead asset and a broader pipeline, positioning itself in the competitive but high-potential field of targeted immunotherapy.

Proprietary AI-guided protein engineering platforms for the discovery and optimization of multi-specific soluble T cell receptors (TCRs). The platform is designed to engineer TCRs for ultra-high affinity, enhanced stability, and improved safety profiles, enabling targeting of intracellular antigens.

Engimmune competes in the emerging field of soluble TCR/bi-specific engagers against companies like Immunocore (with an approved TCR bispecific), Affimed, and other biotechs. It also faces indirect competition from TCR-T cell therapy developers and bispecific antibody companies. Its differentiation lies in its AI-driven engineering focus on multi-specificity, affinity, and stability.